Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Not Tempted To Join COVID-19 Vaccines Race

No Longer Has Capabilities After GSK Asset Swap

Executive Summary

While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.

You may also be interested in...



Novartis Steps Up To Plate To Produce Pfizer/BioNTech COVID-19 Vaccine

In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.

CanSino Confirms Immune Response For Coronavirus Vaccine But Safety Concerns Remain

Latest clinical results show that CanSino's adeno-associated virus coronavirus vaccine appears to be safe and that it induced an immune response in most subjects.

New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost

While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel